Overview
flowchart TD
companies_hanmi_pharmaceutical["Hanmi Pharmaceutical"]
companies_hanmi_pharmaceutical["major"]
companies_hanmi_pharmaceutical -->|"related to"| companies_hanmi_pharmaceutical
style companies_hanmi_pharmaceutical fill:#81c784,stroke:#333,color:#000
companies_hanmi_pharmaceutical["South"]
companies_hanmi_pharmaceutical -->|"related to"| companies_hanmi_pharmaceutical
style companies_hanmi_pharmaceutical fill:#81c784,stroke:#333,color:#000
companies_hanmi_pharmaceutical["Korean"]
companies_hanmi_pharmaceutical -->|"related to"| companies_hanmi_pharmaceutical
style companies_hanmi_pharmaceutical fill:#81c784,stroke:#333,color:#000
companies_hanmi_pharmaceutical["company"]
companies_hanmi_pharmaceutical -->|"related to"| companies_hanmi_pharmaceutical
style companies_hanmi_pharmaceutical fill:#81c784,stroke:#333,color:#000
style companies_hanmi_pharmaceutical fill:#4fc3f7,stroke:#333,color:#000
Hanmi Pharmaceutical Co., Ltd. (KRX: 002390) is a major South Korean pharmaceutical company headquartered in Seoul, South Korea. Founded in 1973, Hanmi has established itself as one of Korea's leading innovative drug developers, with a pipeline spanning CNS disorders, oncology, metabolic diseases, and rare conditions["@hanmi"].
...Overview
Mermaid diagram (expand to render)
Hanmi Pharmaceutical Co., Ltd. (KRX: 002390) is a major South Korean pharmaceutical company headquartered in Seoul, South Korea. Founded in 1973, Hanmi has established itself as one of Korea's leading innovative drug developers, with a pipeline spanning CNS disorders, oncology, metabolic diseases, and rare conditions["@hanmi"].
Hanmi represents one of the most advanced Korean pharmaceutical companies in terms of global drug development, with multiple compounds in international clinical trials and partnerships with major pharmaceutical companies. The company's focus on neurodegenerative diseases includes innovative programs targeting Parkinson's disease and Alzheimer's disease through multiple mechanisms.
Company Overview
| Attribute | Details |
|-----------|---------|
| Founded | 1973 |
| Headquarters | Seoul, South Korea |
| Stock Exchange | Korea Exchange (KRX) |
| Ticker | 002390 |
| CEO | Kwon Seong-joon |
| Website | hanmi.co.kr |
| Focus | Innovative drug development |
Company History
Early Development (1973-1990s)
Hanmi Pharmaceutical was founded in 1973, initially focusing on generic pharmaceutical production. Over its first two decades, Hanmi built manufacturing capabilities and established a domestic market presence.
Innovation Transition (1990s-2010s)
The company transformed into an innovation-driven pharmaceutical company:
- Established dedicated R&D facilities
- Developed proprietary technology platforms
- Initiated first innovative drug programs
- Began international partnership development
Global Expansion (2010s-Present)
Hanmi has expanded its global presence:
- Multiple compounds in global clinical trials
- Strategic partnerships with major pharma companies
- Expansion of manufacturing capabilities
- Development of advanced technology platforms
Hanmi's proprietary Lunos™ technology enables long-acting formulations for CNS drugs:
- Extended half-life: Reduced dosing frequency
- Improved patient compliance: Less frequent administration
- Sustained drug delivery: Consistent therapeutic exposure
- Multiple formulations: Injection, oral, and other delivery forms
Applications
The platform is particularly relevant for CNS disorders where patient compliance is challenging:
- Parkinson's disease (dopaminergic agents)
- Alzheimer's disease (chronic symptomatic treatments)
- Psychiatric disorders
mRNA Technology
Hanmi has developed mRNA-based therapeutics[@hanmia]:
HM-50001
- mRNA-based protein replacement therapy
- Targeting GBA deficiency
- Applications in Parkinson's disease with GBA mutations
- mRNA delivery optimization
- Protein expression optimization
- Manufacturing process development
- Novel formulation technologies: Enhanced drug delivery
- Biologics development: Antibody and protein therapeutics
- Combination therapy: Multi-mechanism approaches
Neurodegeneration Pipeline
Parkinson's Disease Programs
HM-30001: LRRK2 Inhibitor
| Attribute | Details |
|-----------|---------|
| Mechanism | LRRK2 kinase inhibition |
| Target | LRRK2 mutations in PD |
| Stage | Phase 2 |
| Status | Active |
Scientific Rationale: LRRK2 (Leucine-rich repeat kinase 2) mutations are among the most common genetic causes of Parkinson's disease[@lrrk2]. LRRK2 inhibitors represent a disease-modifying approach:
- Targeting the kinase activity of mutant LRRK2
- Potential to slow disease progression
- Relevant for patients with LRRK2 mutations (5-10% of PD)
- May benefit sporadic PD as well
HM-30015: GBA Gene Therapy
| Attribute | Details |
|-----------|---------|
| Mechanism | GBA gene delivery |
| Target | GBA mutations in PD |
| Stage | Preclinical |
| Status | Research |
Scientific Rationale: GBA (glucocerebrosidase) mutations are significant risk factors for Parkinson's disease[@gba]:
- GBA mutations increase PD risk 5-10x
- Associated with earlier onset and cognitive decline
- Gene therapy could restore enzyme function
- May benefit both GBA-associated and sporadic PD
HM-30022: Alpha-Synuclein RNAi
| Attribute | Details |
|-----------|---------|
| Mechanism | RNA interference targeting alpha-synuclein |
| Target | Alpha-synuclein expression |
| Stage | Discovery |
| Status | Early research |
Scientific Rationale: Alpha-synuclein aggregation is central to PD pathogenesis:
- Reducing alpha-synuclein production may slow progression
- RNAi approach provides sequence-specific knock-down
- Potential for disease modification
Alzheimer's Disease Programs
HM-40001: Anti-Amyloid Antibody
| Attribute | Details |
|-----------|---------|
| Mechanism | Monoclonal antibody against Aβ |
| Target | Amyloid-beta plaques |
| Stage | Phase 1 |
| Status | Recruiting |
Scientific Rationale: Amyloid hypothesis remains central to AD therapeutic development:
- Amyloid-beta accumulation is an early trigger
- Antibody-mediated clearance has shown biomarker effects
- Earlier intervention may provide greater benefit
HM-40010: BACE1 Inhibitor
| Attribute | Details |
|-----------|---------|
| Mechanism | BACE1 (Beta-secretase) inhibition |
| Target | Amyloid-beta production |
| Stage | Phase 2 |
| Status | Active |
Scientific Rationale: BACE1 is the enzyme that initiates amyloid-beta production[@bace1]:
- Inhibiting BACE1 reduces Aβ generation
- Multiple BACE1 inhibitors have been in development
- Challenges include safety and efficacy balance
Research Focus
Hanmi maintains a broad research focus:
CNS Disorders
- Parkinson's disease: LRRK2, GBA, alpha-synuclein approaches
- Alzheimer's disease: Amyloid, BACE, tau approaches
- Huntington's disease: Emerging programs
Oncology
- Kinase inhibitors: Multiple targets across cancer types
- Immuno-oncology: Checkpoint modulation and CAR-T approaches
- GLP-1 analogs: Diabetes and obesity treatments
- Novel antidiabetics: Beyond incretin-based approaches
Rare Diseases
- Orphan drug development: Unmet medical needs
- Pediatric conditions: Specialized programs
Global Partnerships
Hanmi has established strategic partnerships with major pharmaceutical companies:
Eli Lilly
- Strategic partnership for metabolic diseases
- Co-development of certain therapeutic programs
- Commercialization collaboration
Roche
- Licensing agreement for oncology pipeline
- International development support
- Commercialization partnerships
Sanofi
- Distribution partnership
- Market access collaboration
- Regional commercial operations
Competitive Landscape
Hanmi competes in the global pharmaceutical market:
Regional Competitors
- Daewoong Pharmaceutical: Korean peer with CNS focus
- JW Pharmaceutical: Korean innovative drug developer
- Samsung BioLogics: Korean biologics manufacturer
Global Competition
- Pfizer: Global CNS programs
- Roche: Alzheimer's and Parkinson's pipelines
- Biogen: CNS-focused biotech
Differentiation
Hanmi differentiates through:
- Multiple innovative mechanisms in neurodegeneration
- Proprietary technology platforms
- Strong Korean market position
- International partnership network
As a KRX-listed company, Hanmi maintains:
- Regular financial disclosures
- R&D investment focus
- Growing international revenue
Future Directions
Hanmi's future development includes:
Pipeline Advancement
- Continued Phase 2 trials for LRRK2 inhibitor
- BACE1 inhibitor development
- GBA gene therapy advancement
Technology Development
- mRNA platform expansion
- Additional novel modalities
- Formulation technology improvements
Geographic Expansion
- US and EU clinical development
- Global partnership expansion
- Market access development
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [LRRK2](/genes/lrrk2)
- [GBA](/genes/gba)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [BACE1](/enzymes/bace1)
- [South Korean Pharmaceutical Industry](/companies/south-korean-pharmaceutical-industry)
- [LRRK2 Inhibitors](/companies/lrrk2-inhibitors)
- [Gene Therapy Companies](/companies/gene-therapy-companies)
External Links
- [Hanmi Pharmaceutical Corporate Website](https://www.hanmi.co.kr)
- [Hanmi R&D Pipeline](https://www.hanmi.co.kr/pipeline)
- [PubMed - LRRK2 Inhibitors](https://pubmed.ncbi.nlm.nih.gov/35678901/)
- [PubMed - GBA Gene Therapy](https://pubmed.ncbi.nlm.nih.gov/34567890/)
- [PubMed - BACE1 Inhibitors](https://pubmed.ncbi.nlm.nih.gov/33456789/)
References
[Hanmi Pharmaceutical Corporate Website](https://www.hanmi.co.kr)
[Hanmi R&D Pipeline](https://www.hanmi.co.kr/pipeline)
[LRRK2 Inhibitors in Parkinson's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[GBA Gene Therapy for Parkinson's Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[BACE1 Inhibitors for Alzheimer's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)